Weeks af­ter launch­ing Aeter­na Zen­taris castoff, Strong­bridge turns around and sells rights to No­vo Nordisk — at a pre­mi­um

Reach­ing what ap­pears to be an end to its wind­ing jour­ney to mar­ket, the growth hor­mone drug Macrilen has just found a new home in the US and Cana­da.

No­vo Nordisk has scooped up re­gion­al rights to the as­set from Strong­bridge Bio­phar­ma, which bought them from Aeter­na Zen­taris this Jan­u­ary for $24 mil­lion up­front and some mile­stones. That’s a bar­gain price com­pared to what the Dan­ish drug­mak­er is of­fer­ing now: $145 mil­lion, plus an eq­ui­ty in­vest­ment worth more than $36 mil­lion as well as tiered roy­al­ties through 2027.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN